Cargando…

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases, is caused by the disruption of hepatic lipid homeostasis. It is associated with insulin resistance as seen in type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) is an incretin that increases insulin sensitivity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jinmi, Hong, Seok-Woo, Rhee, Eun-Jung, Lee, Won-Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3428412/ https://www.ncbi.nlm.nih.gov/pubmed/22950055 http://dx.doi.org/10.4093/dmj.2012.36.4.262

Ejemplares similares

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
por: Nevola, Riccardo, et al.
Publicado: (2023)

Autonomic Imbalance Increases the Risk for Non-alcoholic Fatty Liver Disease
por: Jung, Inha, et al.
Publicado: (2021)

Increased risk for development of coronary artery calcification in subjects with non-alcoholic fatty liver disease and systemic inflammation
por: Kim, Jihyun, et al.
Publicado: (2017)

Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases
por: Park, Ji-Won, et al.
Publicado: (2021)

Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Zhu, Yuan, et al.
Publicado: (2021)

The Relationship between 10-Year Cardiovascular Risk Calculated Using the Pooled Cohort Equation and the Severity of Non-Alcoholic Fatty Liver Disease
por: Lee, Jeong In, et al.
Publicado: (2016)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Association of Serum Adipocyte-Specific Fatty Acid Binding Protein with Fatty Liver Index as a Predictive Indicator of Nonalcoholic Fatty Liver Disease
por: Jeon, Won Seon, et al.
Publicado: (2013)

Non-alcoholic fatty liver disease in polycystic ovary syndrome women
por: Won, Young Bin, et al.
Publicado: (2021)

Higher association of coronary artery calcification with non-alcoholic fatty liver disease than with abdominal obesity in middle-aged Korean men: the Kangbuk Samsung Health Study
por: Lee, Min-Kyung, et al.
Publicado: (2015)

Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
por: Lee, Byung-Wan, et al.
Publicado: (2020)

Impact of hypothyroidism on the development of non-alcoholic fatty liver disease: A 4-year retrospective cohort study
por: Lee, Kil Woo, et al.
Publicado: (2015)

Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
por: Sofogianni, Areti, et al.
Publicado: (2020)

Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison
por: Jung, Han Na, et al.
Publicado: (2022)

The effects of the voglibose on non-alcoholic fatty liver disease in mice model
por: Bae, Jaehyun, et al.
Publicado: (2022)

GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
por: Rezaei, Shahla, et al.
Publicado: (2021)

Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease
por: Kim, Jeong Woo, et al.
Publicado: (2020)

Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)
por: Cho, Yongin, et al.
Publicado: (2022)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Exendin-4 Inhibits the Expression of SEPP1 and Fetuin-A via Improvement of Palmitic Acid-Induced Endoplasmic Reticulum Stress by AMPK
por: Lee, Jinmi, et al.
Publicado: (2015)

Activation of AMP-Activated Protein Kinase Attenuates Tumor Necrosis Factor-α-Induced Lipolysis via Protection of Perilipin in 3T3-L1 Adipocytes
por: Hong, Seok-Woo, et al.
Publicado: (2014)

Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease
por: Shin, Hee Kyung, et al.
Publicado: (2021)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

The impact of non-alcoholic fatty liver disease and metabolic syndrome on the progression of coronary artery calcification
por: Cho, Yun Kyung, et al.
Publicado: (2018)

GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
por: Yu, Ji Hee, et al.
Publicado: (2022)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

Association between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity
por: Kim, Seok-hyung, et al.
Publicado: (2020)

Non–Laboratory-Based Self-Assessment Screening Score for Non-Alcoholic Fatty Liver Disease: Development, Validation and Comparison with Other Scores
por: Lee, Yong-ho, et al.
Publicado: (2014)

Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects
por: Zhong, Xia, et al.
Publicado: (2019)

Identifying Candidate Flavonoids for Non-Alcoholic Fatty Liver Disease by Network-Based Strategy
por: Lee, Won-Yung, et al.
Publicado: (2022)

Deficiency of Sphingosine-1-Phosphate Reduces the Expression of Prohibitin and Causes β-Cell Impairment via Mitochondrial Dysregulation
por: Hong, Seok-Woo, et al.
Publicado: (2018)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
por: Al-Zamel, Noura, et al.
Publicado: (2019)

Predicted pro-inflammatory hs-CRP score and non-alcoholic fatty liver disease
por: Okekunle, Akinkunmi Paul, et al.
Publicado: (2023)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
por: Seo, Mi Hae, et al.
Publicado: (2016)

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review
por: Lv, Xiaodan, et al.
Publicado: (2020)

Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea
por: Jeong, Eun Haeng, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ftm93ga2ql16log5nlqr8cs0n9